Biography as Biology in Drug Development: Bio-Biographical Response States for Translational Pharmacology

Abstract Molecular stratification has improved drug development, yet treatment effects remain heterogeneous within apparently similar patients. We propose that selected lived exposures be studied as bio-biographical response states: prospectively measured combinations of experience, candidate mediator biology, and treatment context that may modify efficacy, toxicity, adherence, or end point ascertainment. This Perspective translates the concept into a falsifiable development framework. It defines pathway-specific hypotheses, consolidates trial-feasible measures, uses immuno-oncology as an implementation test case, and specifies stage-appropriate evidentiary gates. The framework does not treat adversity as destiny or assume that association establishes causation. It requires reliable measurement, formal interaction estimates, competing-explanation analyses, independent replication, and a defined decision consequence. Used with these guardrails, biography can complement molecular pharmacology by revealing reproducible host states that otherwise appear as unexplained response heterogeneity.